Composition for the oral administration of magnesium, in association with a composition for treating type 2 diabetes or the complications thereof

Abstract

The invention relates to a specific composition for oral administration of magnesium, for use in the treatment of type 2 diabetes or the complications thereof, in association with a composition for treating type 2 diabetes or the complications thereof.

Claims

1. A method for delaying the onset or progression of long term type 2 diabetes complications selected from diabetic nephropathy, diabetic retinopathy, or diabetic cardiovascular disease comprising orally administering a magnesium matrix composition to a patient in need thereof thereby increasing intestinal and renal tolerance of long-term magnesium intake, wherein said magnesium matrix composition is a tablet consisting of the following components: a) TABLE-US-00011 MgCl.sub.2n(H.sub.2O) 725.0 mg; HPMC 183.0 mg; mono-diglyceride behenate 20.0 mg; anhydrous lactose 11.0 mg; anhydrous colloidal silica 11.0 mg; and a protective coating which slows down the dissolution of the magnesium at the gastric level, where n is a whole or fractional real number greater than 0 and less than or equal to 6; b) TABLE-US-00012 MgCl.sub.29/2H.sub.2O 725.0 mg; HPMC 185.2 mg; mono-diglyceride behenate 19.8 mg; anhydrous lactose 11.0 mg; anhydrous colloidal silica 11.0 mg; and a protective coating which slows down the dissolution of the magnesium at the gastric level; c) TABLE-US-00013 MgCl.sub.29/2H.sub.2O 725.0 mg; HPMC 185.0 mg; mono-diglyceride behenate 20.0 mg; anhydrous lactose 11.0 mg; anhydrous colloidal silica 11.0 mg; and a protective coating which slows down the dissolution of the magnesium at the gastric level; d) TABLE-US-00014 MgCl.sub.29/2H.sub.2O 725.0 mg; HPMC 183.0 mg; mono-diglyceride behenate 20.0 mg; anhydrous lactose 11.0 mg; anhydrous colloidal silica 11.0 mg; and a protective coating which slows down the dissolution of the magnesium at the gastric level; or e) TABLE-US-00015 MgCl.sub.29/2H.sub.2O 725.0 mg; HPMC 190.0 mg; mono-diglyceride behenate 21.5 mg; anhydrous lactose 10.0 mg; anhydrous colloidal silica 10.0 mg; pyridoxine hydrochloride 6.0 mg; and a protective coating which slows down the dissolution of the magnesium at the gastric level.

2. The method of claim 1, wherein the protective coating is a film-coating with one or more layers.

3. The method of claim 1, wherein said protective coating is a film-coating with one or more layers and represents 1.3% to 7.5% by weight relative to the weight of the matrix composition.

4. The method of claim 1, wherein said protective coating is: (a) a monolayer film-coating of shellac, or (b) a two-layer film-coating, each layer comprising a substance chosen from shellac, cellulose ethers, and mixtures thereof.

5. The method of claim 1, wherein said tablet is: (I) a tablet with a homogeneous structure containing the magnesium chloride hydrate, or (II) a tablet with a composite structure comprising: (a) a core structure which is gastroresistant, or housed in a gastroresistant shell, said core structure containing 80% to 40% of the magnesium chloride hydrate, and (b) an external layer that is hydrophilic, which dissolves in the stomach and contains 20% to 60% of the magnesium chloride hydrate.

6. The method of claim 1, wherein n is between 2 and 6.

7. The method of claim 1, wherein the magnesium matrix composition is administered in combination with a composition comprising, in a pharmaceutically acceptable medium, at least one pharmaceutically active agent selected from the group consisting of agents which stimulate insulin secretion, insulin sensitizers, agents which decrease glucogenesis, dipeptidyl peptidase-4 inhibitors and alpha-glucosidase inhibitors.

8. The method of claim 7, wherein the composition comprises at least two pharmaceutically active agents.

9. The method of claim 1, said method delaying the onset or progression of diabetic nephropathy.

10. The method of claim 1, said method delaying the onset or progression of diabetic retinopathy.

11. The method of claim 1, said method delaying the onset or progression of diabetic cardiovascular disease.

12. The method of claim 1, wherein n is between 3 and 11/2.

13. The method of claim 1, wherein n is 6/2, 7/2, 8/2, 9/2 or 10/2.

14. The method of claim 1, wherein n is 9/2.

15. The method of claim 7, wherein said magnesium matrix composition and said composition are administered simultaneously, separately or in a manner spread out over time.

Description

DESCRIPTION OF THE FIGURE

(1) FIG. 1. Magnesium elimination in the urine expressed in mg over 24 h after administration of two products: a sustained-release product according to the invention (2 tablets containing 50 mg of magnesium) and an immediate-release reference product A (3 tablets containing 100 mg of magnesium).

DETAILED DESCRIPTION OF THE INVENTION

(2) Since the absorption of the magnesium occurs all along the intestinal tract, from the duodenum to the large intestine, and is optimal in the ileum (i.e., the final part of the small intestine), the transit time varying with the type of meal, and since, in the abovementioned dissolution system A at T=2 h, there is still administered Mg which has not yet dissolved, an optimally absorbable amount of the magnesium released (in the Mg.sup.2+ form) reaches the ileum and crosses the intestinal wall, according to the invention.

(3) According to the invention, dissolution kinetics are obtained according to which the Mg release occurs (i) relatively slowly and (ii) gradually as soon as the gastric phase occurs. These kinetics exhibit a particular dissolution, on the one hand, in the stomach (thereby prohibiting a gastroresistant film-coating) and, on the other hand, in the small intestine.

(4) The matrix according to the invention and its coating do not comprise any product prohibited by the European and international regulations relating to food supplements. In particular, said matrix and said coating are free of PCV and polyvinylpyrrolidone.

(5) The substance B1 is hydroxypropylmethylcellulose (HPMC). It is used here in a quality which is suitable for pharmaceutical or food use.

(6) The substance B2 is glyceryl behenate, which is a mixture essentially consisting of behenic acid monoglyceride and diglyceride (other nomenclature: mono-diglyceride behenate) and is known under the European additive name E471. The substance B2 is also used here in a quality which is suitable for pharmaceutical or food use.

(7) According to the invention, the B1/B2 weight ratio is between 180/22.2=8.1/1 and 190/19.8=9.6/1. Advantageously, it is recommended that said weight ratio be between 8.5/1 and 9.3/1. Preferably, the B1/B2 weight ratio will be between 8.7/1 and 9.2/1, for example, 8.8/1, 9/1 or 9.15/1.

(8) The lactose, constituent C1, is advantageously anhydrous. Likewise, the colloidal silica, constituent C2, is advantageously anhydrous. In practice, it is rather preferred for the C1/C2 weight ratio in the matrix of the invention to be close to 1/1 and better still equal to 1/1.

(9) The composition comprising magnesium according to the invention may correspond to:

(10) (I) tablets with a homogeneous structure containing all of the magnesium source, or

(11) (II) tablets with a composite (or heterogeneous) structure comprising:

(12) (a) a first structure (or internal core) which is gastroresistant, or housed in a gastroresistant shell, said first structure containing 80% to 40% of the magnesium provided by the magnesium source, and (b) a second structure (or external layer) which is hydrophilic, which dissolves in the stomach and contains 20% to 60% of the magnesium provided by the magnesium source.

(13) The tablets used according to the invention also comprise a coating which is not gastroresistant. It is a film coating which acts (i) to protect the constituents of the bare tablet with respect to the exterior, in particular with respect to impacts, and especially (ii) to slow down the dissolution of the Mg in the gastric phase. This film coating can be made of a single layer, two layers, or even three layers. In order to limit production costs, it is possible for it to be a monolayer. However, a two-layer coating is recommended, in order to have better control of the Mg dissolution. As indicated above, the coating of the matrix generally represents 15 to 75 parts by weight for a magnesium source supplying 90 to 110 parts by weight of Mg (i.e., approximately 1.3% to 7.5% by weight relative to the weight of the matrix). Preferably, it represents 15 to 70 parts by weight, and better still 15 to 45 parts by weight, for 90 to 110 parts by weight of Mg.

(14) The substances recommended here for the coating are shellac and film-forming cellulose ethers such as alkylcelluloses, namely more particularly the mixtures of HPMC and hydroxypropylcellulose (HPC) sold in particular under the names Nutrateric and Opadry. It is also possible to envision a coating consisting of a first layer of shellac and an external layer made of a mixture of alkylcelluloses.

(15) In practice, a coating is recommended which is: (a) a monolayer film coating of shellac (used at 50% by weight in ethanol, the solvent being removed during the film-coating), or (b) a two-layer film coating, each layer comprising a substance chosen from shellac, cellulose ethers (in particular HPMC and HPC), and mixtures thereof.

(16) When a two-layer coating is used, the first layer (or internal layer) generally represents 0.5% to 4% by weight relative to the weight of the matrix, and the second layer (or external layer) generally represents 0.5% to 3.5% by weight relative to the weight of said matrix, the two said layers together representing 1.3% to 7.5% by weight relative to the weight of said matrix.

(17) According to the invention, a composition, in film-coated tablet form, which gradually and continuously releases magnesium is recommended. This composition advantageously consists of: a matrix (constituting in particular a core) comprising: (A) 90 to 110 parts by weight of magnesium, the magnesium source being MgCl.sub.2.nH.sub.2O, where n is a real number greater than 0 and less than or equal to 6, preferably n is between 2 and 6, and better still from 3 to 11/2, advantageously n is 6/2, 7/2, 8/2, 9/2 or 10/2, and in particular 9/2, (B1) 180 to 190 parts by weight of hydroxypropylmethylcellulose, (B2) 19.8 to 22.2 parts by weight of glyceryl behenate, (C1) 10 to 12 parts by weight of lactose, and (C2) 10 to 12 parts by weight of colloidal silica; and a film coating of: (D) 15 to 45 parts by weight of a substance chosen from shellac, cellulose ethers (in particular HPMC and HPC), and mixtures thereof.

(18) It is recommended to store the composition used according to the invention at a temperature below 40 C., and preferably at a temperature below or equal to 25 C.

(19) The composition comprising magnesium is used according to the invention in combination with a composition intended for treating type 2 diabetes or complications thereof.

(20) The composition intended for treating type 2 diabetes or complications thereof is, according to a particular mode of the invention, a composition for oral administration.

(21) It comprises, in a pharmaceutically acceptable medium, at least one pharmaceutically active agent intended for treating type 2 diabetes or complications thereof.

(22) The pharmaceutically active agent intended for treating type 2 diabetes may be in particular chosen from agents which stimulate insulin secretion, insulin sensitizers, agents which decrease glucogenesis, dipeptidyl peptidase-4 inhibitors and alpha-glucosidase inhibitors.

(23) The agents which stimulate insulin secretion may be chosen in particular from sulfonylureas and glinides. By way of example of sulfonylureas, mention may in particular be made of carbutamide (Glucidoral), glibenclamide/glyburide (Daonil, Euglucan), glibomuride (Glutril), gliclazide (Diamicron), glimepiride (Amarel) and glipizide (Glibenese). By way of example of glinides, mention may in particular be made of repaglinide (NovoNorm).

(24) The agents which decrease glucogenesis are generally represented by biguanides, and mention may in particular be made of metformin (Glucophage, Stagid).

(25) Among the dipeptidyl peptidase-4 inhibitors, mention may in particular be made of saxagliptin, sitaglyptin and vidagliptin.

(26) The insulin sensitizers are represented mainly by thiazolidinediones (TZDs). Mention may in particular be made of pioglitazone (Actos) or rosiglitazone (Avandia).

(27) Among the alpha-glucosidase inhibitors, mention may in particular be made of acarbose (Glucor) or miglitol (Diastabol).

(28) Diabetic patients are, moreover, known to be a population at risk regarding the development of pathological cardiovascular conditions, in particular atherosclerosis. This is partly due to a greater susceptibility to factors such as hyperlipidemia or hypercholesterolemia. Thus, decreasing the level of low-density lipoprotein-cholesterol (LDL-cholesterol) in the serum is in this respect the first therapeutic approach. It may also be important to identify patients who have a low level of high-density lipoprotein-cholesterol (HDL-cholesterol) and/or high levels of triglycerides. It has in particular been shown that triglyceride-rich lipoproteins originating either from the liver (VLDL) or from the intestine (chylomicron) have a high atherogenic risk.

(29) According to one particular mode of the invention, the composition intended for treating type 2 diabetes or complications thereof may comprise a pharmaceutically active agent chosen from compounds which decrease the lipid or cholesterol level, such as PPARalpha antagonists, in particular fibrates (for example, fenofibrate, bezafibrate, ciprofibrate or gemfibrozyl), inhibitors of HmGCoA (Hydroxymethylglutaryl Coenzyme A reductase), such as statins (for example, atorvastatin, simvastatin or fluvastatin), cholesterol absorption inhibitors (for example, ezetimibe or phytosterols), CETP (Cholesteryl Ester Transfer Protein) inhibitors (for instance, torcetrapib), ACAT (AcylCoA-Cholesterol Acyl Transferase) inhibitors, MTP (Microsomal Triglyceride Transfer Protein) inhibitors, bile acid-sequestering agents (cholestyramine), etc.

(30) According to another particular mode of the invention, the composition intended for treating type 2 diabetes or complications thereof may comprise a pharmaceutically active agent chosen from anti-hypertensive and hypotensive agents, such as ACE (Angiotensin-Converting Enzyme) inhibitors (for instance, captopril, enalapril, ramipril or quinapril), angiotensin II receptor antagonists (for example, losartan, valsartan, telmisartan, eposartan, irbesartan, etc.), beta-blockers (for example, atenolol, metoprolol, labetalol, propranolol), diuretics (for example, furosemide, indapamide, hydrochlorthiazide, or anti-aldosterone), vasodilators such as alpha-receptor blockers (such as prazosin or urapidil) or minoxidil, calcine channel blockers (for instance, nifedipine, felodipine, amlodipine, diltizem or verapamil), etc.

(31) The composition intended for treating type 2 diabetes or complications thereof may comprise at least two pharmaceutically active agents intended for treating type 2 diabetes or complications thereof. Thus, a composition intended for treating type 2 diabetes or complications thereof may comprise, in the same pharmaceutical form or in separate pharmaceutical forms, metformin and a sulfonylurea, a biguanide or a thiazolidinedione. As examples of combinations of active agents, mention may be made of the following products: metformin+glibenclamide/glyburide, metformin+glipizide, metformin+pioglitazone, metformin+rosiglitazone, metformin+sitagliptin, and metformin+vidagliptin. Thus, a composition intended for treating type 2 diabetes or complications thereof may comprise, optionally in the same pharmaceutical form or in several pharmaceutical forms, at least one therapeutic agent for treating type 2 diabetes, as defined above, in particular chosen from agents which stimulate insulin secretion, insulin sensitizers, agents which decrease glucogenesis, alpha-glucosidase inhibitors, and at least one anti-hypertensive or hypotensive agent, as defined above, such as angiotensin II receptor antagonists.

(32) Many pharmaceutical products for treating type 2 diabetes are already on the market. They are generally administered orally.

(33) The present invention therefore makes it possible to treat, in particular to decrease, the effects of type 2 diabetes, and/or to treat at least one of the complications thereof, in particular cardiovascular diseases, hypertension, retinopathy, nephropathy, depression and/or diabetic foot ulcers.

(34) According to one mode of the invention, said compositions are administered simultaneously, separately or in a manner spread out over time. The compositions may therefore be administered simultaneously (but separately), or sequentially.

(35) The term sequential is intended to mean an application, separated over time, of the composition comprising the magnesium and the pharmaceutical composition comprising at least one pharmaceutically active agent for treating type 2 diabetes or complications thereof. The user will therefore be able to successively administer the composition comprising the magnesium, and the pharmaceutical composition comprising at least one pharmaceutically active agent for treating diabetes or complications thereof, after a few seconds or after several hours on the same day, in particular within a period ranging from 1 hour to 3 days. According to one alternative, firstly the composition comprising the pharmaceutically active agent for treating type 2 diabetes or complications thereof is administered, and secondly the composition comprising the magnesium is administered. According to another alternative, firstly the composition comprising the magnesium is administered and secondly the pharmaceutical composition comprising at least one pharmaceutically active agent for treating type 2 diabetes or complications thereof is administered.

(36) The pharmaceutical composition comprising at least one pharmaceutically active agent for treating type 2 diabetes or complications thereof will be administered, preferably orally, according to the prescribed treatment, and in particular this treatment will depend on the active agent(s) administered and on the patient.

(37) The composition comprising the magnesium and described above generally comprises between 50 mg and 100 mg of magnesium. Preferably, this composition is administered such that 100 to 500 mg, preferably 100 to 200 mg, of magnesium per day are administered to the subject. Advantageously, one to ten tablets are administered per day, for example in the morning and/or the evening, preferably the morning or the morning and the evening. According to one embodiment, one or two tablets, or even up to 4 or 5 tablets, may be administered once or twice a day. According to another particular embodiment, when the tablet comprises 50 mg of magnesium, from two to four tablets may be administered per day, advantageously in the morning and/or the evening, preferably from two to four tablets only in the morning or alternatively one or two in the morning and one or two in the evening. According to another particular embodiment, when the tablet comprises 100 mg of magnesium, one to two tablets may be administered per day, advantageously in the morning and/or the evening.

(38) In one embodiment, the term treatment or treating denotes an improvement in or the prophylaxis of type 2 diabetes or in particular one of the complications thereof. In another embodiment, treatment or treating denotes an improvement in, the prophylaxis of, or the inversion of at least one measurable physical parameter associated with the disease or with the disorder being treated, which is not necessarily discernible in or by the subject treated. In another embodiment, treatment or treating denotes the inhibition or the slowing down of the progression of type 2 diabetes or one of the complications thereof. In another embodiment, treatment or treating denotes a delay in the appearance of at least one of the complications of type 2 diabetes, in particular cardiovascular diseases (such as heart rate disorders, arteritis, or atherosclerosis), hypertension, retinopathy, nephropathy, depression or diabetic foot ulcer. In particular, when it is a question of diabetic foot ulcer, the present invention can be adapted to the prevention, a delay in appearance, or a decrease in the risk of developing a diabetic food ulcer.

(39) In one embodiment, the compositions are administered as a curative measure. In the present context, curative denotes a reduction in the effects of type 2 diabetes and/or a decrease in the development or worsening of one of the complications of type 2 diabetes, in particular cardiovascular diseases (such as heart rate disorders, arteritis, or atherosclerosis), hypertension, retinopathy, nephropathy, depression and foot ulcers, and more specifically cardiovascular diseases (such as heart rate disorders, arteritis, or atherosclerosis), hypertension, retinopathy, nephropathy and depression.

(40) A subject of the present invention is also a method for treating type 2 diabetes or one of the complications thereof, in which a composition comprising magnesium, as defined above, in combination with a pharmaceutical composition comprising at least one pharmaceutically active agent for treating type 2 diabetes or complications thereof, is administered to a patient suffering from type 2 diabetes and optionally one of the complications thereof, it being possible for said compositions to be administered simultaneously (but separately), or sequentially.

(41) For the purpose of the present invention, the term patient or subject is intended to mean any mammal, and more particularly a male or female human being.

(42) Other advantages and characteristics of the invention will be understood more clearly on reading the following examples. Of course, these examples are not limiting in nature; they are given solely by way of illustration.

(43) The tests relating to the determination of the Mg dissolution kinetics were carried out at 40 C. in vitro by means of the abovementioned system A: 0.1N HCl medium from T=0 to T=2 h, then buffer medium at pH 6.8 from T=2 h to T=8 h.

Example 1

(44) Tablets (containing a dose of 100 mg of magnesium) having the following formulation (the B1/B2 weight ratio being 9.15/1) were prepared, Amt/tab representing the amount (expressed in mg) of each constituent of the tablet.

(45) TABLE-US-00001 Constituents Amt/tab (mg) Core: MgCl.sub.29/2H.sub.2O 725.0 HPMC 183.0 Mono-diglyceride behenate 20.0 Anhydrous lactose 11.0 Anhydrous colloidal silica 11.0 Film coating: Shellac 39.6 Total: 989.60

(46) The dissolution profile of these tablets is as described in the present invention.

(47) Tablets equivalent to those described in detail above are prepared with MgCl.sub.2.6/2H.sub.2O and MgCl.sub.2.7/2H.sub.2O.

Example 2

(48) Tablets (containing a dose of 100 mg of magnesium) having the following formulation (the B1/B2 weight ratio being 9.35/1) were prepared.

(49) TABLE-US-00002 Constituents Amt/tab (mg) Core: MgCl.sub.29/2H.sub.2O 725.0 HPMC 185.2 Mono-diglyceride behenate 19.8 Anhydrous lactose 11.0 Anhydrous colloidal silica 11.0 Film coating: Shellac 39.42 Patent blue 0.03 Total: 992.45

(50) The dissolution profile of these tablets is as described in the present invention.

(51) Tablets equivalent to those described in detail above are prepared with MgCl.sub.2.10/2H.sub.2O and MgCl.sub.2.8/2H.sub.2O.

Example 3

(52) Tablets (containing a dose of 100 mg of magnesium) having the following formulation (the B1/B2 weight ratio being 9.25/1) were prepared.

(53) TABLE-US-00003 Constituents Amt/tab (mg) Core: MgCl.sub.29/2H.sub.2O 725.0 HPMC 185.0 Mono-diglyceride behenate 20.0 Anhydrous lactose 11.0 Anhydrous colloidal silica 11.0 Film coating: Shellac 39.6 Total: 991.60

(54) The dissolution profile of these tablets is as described in the present invention.

(55) Tablets equivalent to those described in detail above are prepared with MgCl.sub.2.6/2H.sub.2O and MgCl.sub.2.7/2H.sub.2O.

Example 4

(56) Tablets (containing a dose of 100 mg of magnesium) having the following formulation were prepared according to the abovementioned modes (the B1/B2 weight ratio being 9.15/1).

(57) TABLE-US-00004 Constituents Amt/tab (mg) Core: MgCl.sub.29/2H.sub.2O 725.0 HPMC 183.0 Mono-diglyceride behenate 20.0 Anhydrous lactose 11.0 Anhydrous colloidal silica 11.0 Film coating 1: Shellac 24.17 Film coating 2: HPMC/HPC mixture 1/3 w/w 17.514 Patent blue 0.016 Total: 991.70

(58) The dissolution profile of these tablets is as described in the present invention.

(59) Tablets equivalent to those described in detail above are prepared with MgCl.sub.2.7/2H.sub.2O and MgCl.sub.2.10/2H.sub.2O.

Example 5

(60) Tablets (containing a dose of 100 mg of magnesium) having the following formulation (the B1/B2 weight ratio being 9.15/1) were prepared.

(61) TABLE-US-00005 Constituents Amt/tab (mg) Core: MgCl.sub.29/2H.sub.2O 725.0 HPMC 183.0 Mono-diglyceride behenate 20.0 Anhydrous lactose 11.0 Anhydrous colloidal silica 11.0 Film coating: 1st layer: Shellac 19.8 2nd layer (external): 19.8 HPMC/HPC mixture 1/4 w/w Total: 989.60

(62) The dissolution profile of these tablets is as described in the present invention.

Example 6

(63) According to the modes of Example 5, tablets containing 50 mg of magnesium and having, for each constituent, an amount which is half that of the homologous constituent of said Example 5 are prepared.

Example 7

(64) Tablets (containing a dose of 100 mg of magnesium) having the following formulation (the B1/B2 weight ratio being 9.15/1) were prepared.

(65) TABLE-US-00006 Constituents Amt/tab (mg) Core: MgCl.sub.29/2H.sub.2O 725.0 HPMC 183.0 Mono-diglyceride behenate 20.0 Anhydrous lactose 11.0 Anhydrous colloidal silica 11.0 Film coating: 1st layer (internal): 19.8 HPMC/HPC 1/3 w/w 2nd layer (external): 19.8 HPMC/HPC mixture 1/4 w/w Total: 989.60

(66) The dissolution profile of these tablets is as described in the present invention.

(67) Tablets equivalent to those described in detail above are prepared with MgCl.sub.2.6/2H.sub.2O and MgCl.sub.2.7/2H.sub.2O.

Example 8

(68) According to the modes of Example 7, tablets containing 50 mg of magnesium and having, for each constituent, an amount which is half that of the homologous constituent of said Example 7 are prepared.

Example 9

(69) Tablets (containing a dose of 100 mg of magnesium) having the following formulation (the B1/B2 weight ratio being 8.8/1) were prepared.

(70) TABLE-US-00007 Constituents Amt/tab (mg) Core: MgCl.sub.29/2H.sub.2O 725.0 HPMC 190.0 Mono-diglyceride behenate 21.5 Anhydrous lactose 10.0 Anhydrous colloidal silica 10.0 Pyridoxine hydrochloride 6.0 Film coating: Shellac 40.0 Total: 1003.0

Example 10

(71) Tablets (containing a dose of 50 mg of magnesium) having the following formulation (the B1/B2 weight ratio being 9.15/1) were prepared.

(72) TABLE-US-00008 Constituents Amt/tab (mg) Core: MgCl.sub.29/2H.sub.2O 362.50 HPMC 91.50 Mono-diglyceride behenate 10.00 Anhydrous lactose 5.50 Anhydrous colloidal silica 5.50 Film coating 1: Shellac (Opaglos NA715G, product 1.3 to 2.2%* sold by Colorcon Film coating 2: HPMC/HPC mixture 1/3 w/w (Opadry VMS, 1.1 to 1.6%* product sold by Colorcon) Yellow 20A38069 0.008 Note *percentage by weight relative to the weight of the bare tablet.

Example 11

(73) Tablets (containing a dose of 50 mg of magnesium) having the following formulation (the B1/B2 weight ratio being 9.15/1) were prepared.

(74) TABLE-US-00009 Constituents Amt/tab (mg) Core: MgCl.sub.29/2H.sub.2O 362.50 HPMC 91.50 Mono-diglyceride behenate 10.00 Anhydrous lactose 5.50 Anhydrous colloidal silica 5.50 Film coating: Shellac (Opaglos NA715G, product 1.7%* sold by Colorcon) Note *percentage by weight relative to the weight of the bare tablet.

(75) The dissolution profile of these tablets is as described in the present invention.

Example 12

(76) Tablets (containing a dose of 50 mg of magnesium) having the following formulation (the B1/B2 weight ratio being 9.15/1) were prepared.

(77) TABLE-US-00010 Constituents Amt/tab (mg) Core: MgCl.sub.29/2H.sub.2O 362.50 HPMC 91.50 Mono-diglyceride behenate 10.00 Anhydrous lactose 5.50 Anhydrous colloidal silica 5.50 Film coating 1: Shellac (Opaglos NA715G, product 1.7* sold by Colorcon) Film coating 2: HPMC/HPC mixture 1/3 w/w (Opadry VMS, 0.5%* product sold by Colorcon) Note *percentage by weight relative to the weight of the bare tablet.

Example 13

(78) The objective of the clinical study was to evaluate the relative bioavailability of the magnesium provided by two orally administered formulations: 2 tablets containing 50 mg of magnesium (magnesium chloride), such as those described in Example 12, according to the invention, i.e., 100 mg of magnesium element, compared with a reference product, product A (3 immediate-release tablets containing 100 mg of magnesium), i.e., 300 mg of magnesium element.

(79) The randomized clinical study was carried out as a double-blind and cross-over study on healthy subjects (men). Each of the volunteers having participated in the study received the two products being studied, with a 48 h window (wash-out) between the two periods of supplementation.

(80) For the purpose of evaluating the bioavailability, the magnesium in the urine collected between 0 and 24 hours after taking the tablets was assayed in order to measure the amount of magnesium eliminated by the body. A standardized diet provided all the subjects with the same amount of magnesium.

(81) Results

(82) All the subjects were included in the statistical analysis of the results since no piece of atypical or aberrant data was revealed that would have justified excluding them from the analysis.

(83) The main criterion for evaluation of the study was the comparison of the distribution of the total magnesium present in the subject's body, i.e., the basal magnesium of the subject, to which was added the magnesium provided by the tablets of Example 12, this being in the urine, compared with the reference product.

(84) The urinary elimination of the magnesium, measured on samples collected sequentially during the 24 hours post-intake, showed homogeneous results, with a power between 73.3% (TO-T5 h) and 96.8% (TO-T24 h).

(85) After 24 hours, the cumulative urinary elimination of the magnesium (i.e., basal magnesium+absorbed magnesium) is, following the consumption of 100 mg of magnesium element provided by the tablets according to the invention, 100.53 mg, whereas it is 117.68 mg after the consumption of 300 mg of magnesium element provided by the reference product A.

(86) Urinary Magnesium

(87) The urinary elimination of the magnesium, measured on samples collected sequentially during the 24 hours following the intake of the product, shows homogeneous results.

(88) The statistical power of this study is between 73% and 97%, which means that the number of subjects was sufficient to see any differences between the treatment groups.

(89) These results, presented cumulatively in FIG. 1, show that the product according to the invention with magnesium provision of 100 mg, i.e., 3 times lower than that of the reference product A (300 mg), makes it possible to obtain a urinary magnesium elimination very close to that of product A; the 200 mg of difference between the two doses are not absorbed and are probably eliminated in the feces.

(90) The magnesium absorption yield is therefore better with the product according to the invention than with the reference product.

CONCLUSION

(91) In this study based on the comparison of the urinary elimination of magnesium (which reflects intestinal absorption), the results indicate that the formulation according to the invention makes it possible to obtain a better bioavailability of the orally administered magnesium compared with the formulation of the product A.

(92) A Better Bioavailabilitya Better Absorption Yield

(93) The results of the study show that the amounts eliminated in the urine are virtually identical with the 100 mg provided by the product according to the invention and with the 300 mg provided by product A, and suggest that the absorption yield is three times higher with the formulation according to the invention and that the difference (approximately 200 mg) was not absorbed and therefore was eliminated in the feces.

(94) An Improvement in Intestinal Tolerance

(95) The greater the amount of magnesium released in the intestine, the more the potential risk of irritation thereof increases, due to the unabsorbed magnesium ions. This irritation can lead to possible digestive disorders such as stomach ache, diarrhea, nausea, etc. Thus, the product according to the invention, by virtue of its low dosage and its better absorption yield, should greatly decrease these risks of adverse effects.

(96) A Better Bioavailability Due to the Formulation According to the Invention

(97) The 100 mg of magnesium provided by the formula according to the invention are found in the urine collected during the 48 hours following the intake, thereby suggesting an excellent bioavailability, capable of maintaining an optimal magnesemia in the long term.

(98) The formulation according to the invention administered at the dose of 100 mg, in comparison with the reference product A containing a dose of 300 mg, therefore allows a better bioavailability, and a better digestive tolerance of the magnesium, which is particularly advantageous for subjects who have or who may have type 2 diabetes or at least one of the complications thereof. The formulation according to the invention in fact allows virtually all of the Mg swallowed to be assimilated by the body for amounts 3 times lower than the reference product, which makes it possible to obtain better intestinal and renal tolerance.

Example 14

(99) The pharmaceutical compositions for oral administration comprising at least one pharmaceutically active agent for treating type 2 diabetes are, for example, chosen from those previously mentioned and sold in particular under the following brand names: Glucophage, Metformine Biogaran, Stagid, Galvus (active agent INN: Vidagliptin), Glucidoral (active agent INN: carbutamide), Daonil (active agent INN: glibenclamide), Amarel (active agent INN: glimepiride), Diamicron (active agent INN: glicazide), NovoNorm (active agent INN: repaglinide), Actos (active agent INN: pioglitazone), Avandia (active agent INN: rosiglitazone), Glucor (active agent INN: acarbose), or Diastabol (active agent INN: miglitol), or else active agent combinations, for instance Glucovance (active agent INN: metformin+glibenclamide), Competact (active agent INN: metformin+pioglitazone), Janumet (active agent INN: metformin+sitagliptin), or Eucreas (active agent INN: metformin+vidagliptin).

(100) These products can therefore, according to the invention, be administered according to the physician's prescription in combination with the tablets described in one of examples 1-12. Preferably, these products containing magnesium are administered such that 100 to 500 mg of magnesium are administered to the subject per day. Advantageously, one to ten tablets are administered per day, for example in the morning and/or evening, preferably the morning or the morning and the evening. According to one embodiment, one or two tablets, or even up to 4 or 5 tablets, can be administered once or twice a day. According to another particular embodiment, when the tablet comprises 50 mg of magnesium, from two to four tablets can be administered per day, advantageously in the morning and/or evening, preferably from two to four tablets only in the morning or alternatively one or two in the morning and one or two in the evening. According to another particular embodiment, when the tablet comprises 100 mg of magnesium, one to two tablets can be administered per day, advantageously in the morning and/or evening.